These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12927925)

  • 1. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.
    Forns X; García-Retortillo M; Serrano T; Feliu A; Suarez F; de la Mata M; García-Valdecasas JC; Navasa M; Rimola A; Rodés J
    J Hepatol; 2003 Sep; 39(3):389-96. PubMed ID: 12927925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.
    Iacobellis A; Ippolito A; Andriulli A
    World J Gastroenterol; 2008 Nov; 14(42):6467-72. PubMed ID: 19030197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.
    Carrión JA; Martínez-Bauer E; Crespo G; Ramírez S; Pérez-del-Pulgar S; García-Valdecasas JC; Navasa M; Forns X
    J Hepatol; 2009 Apr; 50(4):719-28. PubMed ID: 19217183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
    Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    Gambato M; Lens S; Navasa M; Forns X
    J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
    Lodato F; Berardi S; Gramenzi A; Mazzella G; Lenzi M; Morelli MC; Tame MR; Piscaglia F; Andreone P; ; Ballardini G; Bernardi M; Bianchi FB; Biselli M; Bolondi L; Cescon M; Colecchia A; D'Errico A; Del Gaudio M; Ercolani G; Grazi GL; Grigioni W; Lorenzini S; Pinna AD; Ravaioli M; Roda E; Sama C; Vivarelli M
    Aliment Pharmacol Ther; 2008 Aug; 28(4):450-7. PubMed ID: 18549463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
    Crippin JS; McCashland T; Terrault N; Sheiner P; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):350-5. PubMed ID: 11965579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
    Babatin M; Schindel L; Burak KW
    Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
    Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
    Moreno Planas JM; Rubio Gonzalez E; Boullosa Graña E; Garrido Botella A; Barrios Peinado C; Lucena Poza JL; Jiménez Garrido M; Sanchez Turrion V; Cuervas-Mons Martinez V
    Transplant Proc; 2005 Jun; 37(5):2207-8. PubMed ID: 15964380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U
    Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
    Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.